Skip to main content

Table 5 Excess mortality according to CD4 cell count and plasma HIV-1 RNA category among HIV-1 infected participants, after adjusting for ART use

From: Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: Results of analyses from a multicenter randomized trial

  Incidence ofmedical death Estimated excess mortality per 1000 person-years (95% CI) P-value Number needed to treat per year (95% CI) to avert 1 death
HIV-1 uninfected 3.6 Reference - Reference
HIV-1 infected 13.7 10.2 (6.9, 13.5) <.001  
CD4 cell count     
  ≥500 4.8 1.2 (−1.8, 4.2) .44 851
  350-499 13.1 8.9 (3.8, 14.0) <.001 113
  250-349 19.9 15.2 (8.1, 22.2) <.001 66
  <250 42.7 29.3 (13.9, 44.7) <.001 34
HIV-1 RNA     
  HIV-1 <10 K 7.7 2.0 (−1.1, 5.0) .21 509
  10 K-50 K 3.7 −0.6 (−3.4, 2.3) .69 NA
  50 K-100 K 13.9 6.7 (−0.6, 14.0) .071 149
  >100 K 46.9 43.0 (29.6, 56.4) <.001 23
  1. † An interaction term was also present in the model between high HIV viral load and use of ART (p = .002). The excess mortality in the last row applies to those not on ART. For those on ART, mortality was not found to exceed that of HIV-1 uninfected (p = 0.58).